Pilot RCT in 70 patients with RA on abatacept (RZV vs placebo): only 42.3% of vaccinees had a ≥4-fold antibody rise and 10.2% a cellular response; RA flares were similar (68% vs 64%), suggesting the vaccine was safe but responses attenuated.
RCTn = 70
Hawkins et al. Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial